About this trial
This study aims to evaluate the efficacy and safety of non-invasive brain-computer interface (BCI) neuromodulation technique combined with 40Hz audio-visual stimulation on cognitive function in patients with Alzheimer's disease (AD). This is a single-center, randomized, double-blind, sham-controlled trial. A total of 90 participants with Aβ-PET positive AD diagnosed according to NIA-AA criteria will be enrolled and randomly assigned to three groups in a 1:1:1 ratio: (1) 40Hz stimulation group (fixed 40Hz audio-visual stimulation, 60 minutes daily for 6 months), (2) individualized stimulation group (closed-loop BCI with real-time EEG feedback to adjust stimulation parameters, 60 minutes daily for 6 months), and (3) sham stimulation group (inactive stimulation, same duration). The primary outcome is the change in MoCA-B score from baseline to 6 months. Secondary outcomes include changes in cognitive domain-specific assessments (AVLT, STT, DST), multimodal brain imaging, EEG parameters, peripheral blood AD biomarkers, safety, tolerability, and comparison of efficacy between open-loop and closed-loop stimulation.
Eligibility criteria
Qualifiers
Diagnosis of Alzheimer's disease according to the NIA-AA 2018 diagnostic criteria.
Age between 50 and 80 years, inclusive.
Positive Aβ-PET scan result.
Has a stable caregiver who can assist with daily stimulation intervention.
Disqualifiers
History of epilepsy or seizure disorder.
Inability to undergo MRI or presence of significant abnormalities on MRI screening.
Geriatric Depression Scale (GDS) score > 6.
Current suicidal ideation or suicide attempt within the past 6 months.
Trial design
Treatments tested in this trial
- 40Hz Stimulation Group
- Individualized Stimulation Group
- Sham Stimulation Group